Post-earnings recap
Reported
Mon, Feb 28, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may leave investors uncertain about the company's near-term prospects. The stock's reaction indicates cautious sentiment among investors following the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.62 | N/A | -50.49% |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their research and development efforts. They acknowledged the difficulties but did not provide specific future expectations.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its pipeline despite the current challenges.